In Mice, a Rebooted Immunotherapy Safely Links T Cells to their Tumor Targets (2 of 5) (image) American Association for the Advancement of Science Share Print E-Mail Caption The engineered 4-1BBL molecule has strong structural flexibility, allowing it to optimally engage and cluster with T cells. This material relates to a paper that appeared in the Jun. 19, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by C. Claus at Roche Innovation Center Zurich in Schlieren, Switzerland; and colleagues was titled, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy." Credit [Credit: Dr. Philippe Ringler and Prof. Dr. Henning Stahlberg at University of Basel, Center for Cellular Imaging and NanoAnalytics (C-CINA); Dr. Matthias E. Lauer at Roche Innovation Center Basel] Usage Restrictions Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission. Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.